FDA OKs Diabetes Combo Therapy from Lilly and BI
By

The US Food and Drug Administration (FDA) has approved Eli Lilly’s and Boehringer Ingelheim’s Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of Type 2 diabetes in adults. Jentadueto XR is the seventh new treatment from the Boehringer Ingelheim-Lilly Diabetes alliance to be approved by the FDA in the last five years. The companies formed the alliance in 2011.

Jentadueto XR combines 2.5 mg or 5 mg of linagliptin with 1000 mg of metformin. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Metformin, a commonly prescribed initial treatment for Type II diabetes, lowers glucose production by the liver and its absorption in the intestine.

Source: Eli Lilly and Company

Leave a Reply

Your email address will not be published.